Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: Quantification of the antibody response

Journal of Clinical Apheresis

Volumn 30, Issue 1, 2015, Pages 8-14

  Farooqi, Midhat S ^a   Lai, Yongjie ^a   Lancaster, Eric ^a   Schmitt, Sarah E ^a   Sachais, Bruce S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anti GAD; Antibodies; Epilepsy; Plasmapheresis; Seizures

Indexed keywords

AUTOANTIBODY; ETIRACETAM; FERRITIN; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IRON; LAMOTRIGINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXCARBAZEPINE; PREDNISONE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2;

ADULT; ANEMIA; ANIMAL CELL; ANTIBODY RESPONSE; ANTICONVULSANT THERAPY; ANXIETY; ARTICLE; BRAIN CELL CULTURE; CASE REPORT; CONFUSION; DISEASE FREE INTERVAL; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EMBRYO; EPILEPSY; EPILEPTIC AURA; EPILEPTIC DISCHARGE; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IRON BLOOD LEVEL; LEUKOPENIA; LIMIT OF DETECTION; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PROTEIN EXPRESSION; RAT; SEIZURE; TEMPORAL LOBE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; ANIMAL; BLOOD; CELL CULTURE; ENZYMOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; YOUNG ADULT;

ANIMALS; AUTOANTIBODIES; CELLS, CULTURED; EPILEPSY; FEMALE; GLUTAMATE DECARBOXYLASE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; NEURONS; PLASMA EXCHANGE; RATS; YOUNG ADULT;

EID: 84922927376     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21342     Document Type: Article

References (27)

1. Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun 2011;37:79-87.
2. Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic?Brain 2008;131:2536-2537.
3. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988;318:1012-1020.
4. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, Maestre J, Fabien N, Vighetto A, Casamitjana R, Thivolet C, Tavolato B, Antoine J, Trouillas P, Graus F. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001;58:225-230.
5. Matà S, Muscas GC, Naldi I, Rosati E, Paladini S, Cruciatti B, Bisulli F, Paganini M, Mazzi G, Sorbi S, Tinuper P. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008;199:155-159.
6. Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998;352:457.
7. Peltola J, Kulmala P, Isojärvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keränen T, Graus F. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000;55:46-50.
8. Burton AR, Baquet Z, Eisenbarth GS, Tisch R, Smeyne R, Workman CJ, Vignali DA. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol 2010;184(9):4863-4870.
9. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, Aanstoot HJ, Turck CW, Erlich H, Lennon V, Baekkeskov S. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994;180:595-606.
10. Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001;57:780-784.
11. Fernandes M, Munhoz RP, Carrilho PE, Arruda WO, Lorenzoni PJ, Scola RH, Werneck LC, Teive HA. Neurological disorders associated with glutamic acid decarboxylase antibodies: a Brazilian series. Arq Neuropsiquiatr 2012;70:657-661.
12. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998;44:194-201.
13. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007;61:544-551.
14. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-1876.
15. Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, Besana C, Borri A, Tresoldi M, Solimena M, DeCamilli P. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med 1989;320:1499.
16. Brashear HR, Phillips LH 2nd. Autoantibodies to GABAergic neurons and response to TPE in stiff-man syndrome. Neurology 1991;41:1588-1592.
17. Shiraishi H, Motomura M, Iwanaga H, Tsujino A, Nishiura Y, Shirabe S, Nakamura T, Yoshimura T. Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy. Rinsho Shinkeigaku 2002;42:766-770.
18. Mazzi G, Roia DD, Cruciatti B, Matà S, Catapano R. Plasma exchange for anti-GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci 2008;39:229-233.
19. Kobayakawa Y, Tateishi T, Kawamura N, Doi H, Ohyagi Y, Kira J. A case of immune-mediated encephalopathy showing refractory epilepsy and extensive brain MRI lesions associated with anti-glutamic acid decarboxylase antibody. Rinsho Shinkeigaku 2010;50:92-97.
20. Korff CM, Parvex P, Cimasoni L, Wilhelm-Bals A, Hampe CS, Schwitzgebel VM, Michel M, Siegrist CA, Lalive PH, Seeck M. Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: a treatable condition? Arch Neurol 2011;68:1065-1068.
21. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010;18:307-316.
22. Wilcox K S, Buchhalter J, Dichter M A. Properties of inhibitory and excitatory synapses between hippocampal neurons in very low density cultures. Synapse 1994;18:128-151.
23. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67-76.
24. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ. Drug removal by TPE: an evidence-based review. Pharmacotherapy 2007;27:1529-49.
25. Novartis. Oxcarbazepine [package insert]. Novartis, East Hanover, NJ, 2011.
26. GlaxoSmithKline. Lamotrigine [package insert]. GlaxoSmithKline, Research Triangle Park, NC, 2009.
27. Christensen J, Balslev T, Villadsen J, Heinsvig EM, Dam M, Poulsen JH. Removal of 10-hydroxycarbazepine by TPE. Ther Drug Monit 2001;23:374-379.